程序性死亡受体1（PD-1）和程序性死亡配体2（PD-L2）的表达可预测III期结直肠癌患者的复发风险和较差的生存率。
PD-1 and PD-L2 expression predict relapse risk and poor survival in patients with stage III colorectal cancer.
作者信息
Zengin Mehmet, Zergeroğlu Sema, Okcu Oğuzhan, Benek Suat
机构信息
Department of Pathology, Kırıkkale University, Kırıkkale, Turkey.
Recep Tayyip Erdoğan University, Training and Research Hospital, Rize, Turkey.
出版信息
Cell Oncol (Dordr). 2021 Apr;44(2):423-432. doi: 10.1007/s13402-020-00579-5. Epub 2021 Jan 19.
BACKGROUND
Immune responses have long been an area of interest in cancer research. In this study, the effects of programmed cell death-1 (PD-1) and its ligand (PD-L2) on the prognosis of colorectal cancer (CRC) were investigated.
METHODS
Primary tumour specimens of stage III CRC patients operated between 2002 and 2013 were assessed for PD-1 and PD-L2 expression and various clinicopathological and prognostic factors.
RESULTS
We observed a significant relationship between poor prognostic factors and PD-1/PD-L2 expression. These biomarkers were also found to serve as independent risk factors for LIR and MSI. In univariate analysis, relapse-free survival (RFS) and overall survival (OS) rates were found to be poor in PD-1 and PD-L2 positive patients. In multivariate analysis, these biomarkers were found to serve as independent poor prognostic factors for RFS and OS.
CONCLUSIONS
Our data indicate that PD-1 and PD-L2 may serve as independent prognostic survival parameters for CRC patients and may be employed for the design of targeted therapies.
背景
免疫反应长期以来一直是癌症研究的一个热点领域。在本研究中，研究了程序性细胞死亡蛋白1（PD-1）及其配体（PD-L2）对结直肠癌（CRC）预后的影响。
方法
对2002年至2013年间接受手术的III期CRC患者的原发性肿瘤标本进行PD-1和PD-L2表达以及各种临床病理和预后因素的评估。
结果
我们观察到不良预后因素与PD-1/PD-L2表达之间存在显著关系。这些生物标志物还被发现是LIR和MSI的独立危险因素。在单变量分析中，发现PD-1和PD-L2阳性患者的无复发生存率（RFS）和总生存率（OS）较差。在多变量分析中，这些生物标志物被发现是RFS和OS的独立不良预后因素。
结论
我们的数据表明，PD-1和PD-L2可能作为CRC患者独立的预后生存参数，并可用于靶向治疗的设计。
Zotero 插件